AAAAAA
Results:
1-23
|
Results: 23
Authors:
Large, GA
Wilcox, RG
Citation: Ga. Large et Rg. Wilcox, Redefining myocardial infarction, HOSP MED, 62(8), 2001, pp. 510-510
Authors:
Greenbaum, AB
Harrington, RA
Hudson, MP
MacAulay, CM
Wilcox, RG
Simoons, ML
Berdan, LG
Guerci, A
Cokkinos, DV
Kitt, MM
Lincoff, AM
Topol, EJ
Califf, RM
Ohman, EM
Citation: Ab. Greenbaum et al., Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes, J AM COL C, 37(2), 2001, pp. 492-498
Authors:
Storey, RF
Oldroyd, KG
Wilcox, RG
Citation: Rf. Storey et al., Open multicentre study of the P-2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes, THROMB HAEM, 85(3), 2001, pp. 401-407
Authors:
Wilcox, RG
Citation: Rg. Wilcox, ST-segment elevation resolution - a surrogate for infarct vessel patency or myocardial perfusion, but a call for rescue?, EUR HEART J, 22(9), 2001, pp. 722-724
Authors:
Llevadot, J
Giugliano, RP
Antman, EM
Wilcox, RG
Gurfinkel, EP
Henry, T
McCabe, CH
Charlesworth, A
Thompson, S
Nicolau, JC
Tebbe, U
Sadowski, Z
Braunwald, E
Citation: J. Llevadot et al., Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction, EUR HEART J, 22(22), 2001, pp. 2104-2115
Authors:
Giugliano, RP
Llevadot, J
Wilcox, RG
Gurfinkel, EP
McCabe, CH
Charlesworth, A
Thompson, SL
Antman, EM
Braunwald, E
Citation: Rp. Giugliano et al., Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis - Results from InTIME-II, EUR HEART J, 22(18), 2001, pp. 1702-1715
Authors:
White, HD
Simes, RJ
Aylward, PEG
Armstrong, PW
Califf, RM
French, JK
Granger, CB
Marschner, IC
Topol, EJ
Van de Werf, FJ
Wilcox, RG
Citation: Hd. White et al., Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial, LANCET, 358(9296), 2001, pp. 1855-1863
Authors:
Aronow, HD
Topol, EJ
Roe, MT
Houghtaling, PL
Wolski, KE
Lincoff, AM
Harrington, RA
Califf, RM
Ohman, EM
Kleiman, NS
Keltai, M
Wilcox, RG
Vahanian, A
Armstrong, PW
Lauer, MS
Citation: Hd. Aronow et al., Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study, LANCET, 357(9262), 2001, pp. 1063-1068
Authors:
Cannon, CP
McCabe, CH
Wilcox, RG
Bentley, JH
Braunwald, E
Citation: Cp. Cannon et al., Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris, AM J CARD, 87(5), 2001, pp. 636-639
Authors:
Giugliano, RP
McCabe, CH
Antman, EM
Cannon, CP
Van de Werf, F
Wilcox, RG
Braunwald, E
Citation: Rp. Giugliano et al., Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage, AM HEART J, 141(5), 2001, pp. 742-750
Authors:
Akkerhuis, KM
Deckers, JW
Boersma, E
Harrington, RA
Stepinska, J
Mahaffey, KW
Wilcox, RG
Lincoff, AM
Keltai, M
Topol, EJ
Califf, RM
Simoons, ML
Citation: Km. Akkerhuis et al., Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes - Results from PURSUIT, EUR HEART J, 21(5), 2000, pp. 371-381
Authors:
Akkerhuis, KM
Neuhaus, KL
Wilcox, RG
Vahanian, A
Boland, JL
Hoffmann, J
Baardman, T
Nehmiz, G
Roth, U
Klootwijk, APJ
Deckers, JW
Simoons, ML
Citation: Km. Akkerhuis et al., Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation - A phase II study, EUR HEART J, 21(24), 2000, pp. 2042-2055
Authors:
Cannon, CP
McCabe, CH
Wilcox, RG
Langer, A
Caspi, A
Berink, P
Lopez-Sendon, J
Toman, J
Charlesworth, A
Anders, RJ
Alexander, JC
Skene, A
Braunwald, E
Citation: Cp. Cannon et al., Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial, CIRCULATION, 102(2), 2000, pp. 149-156
Authors:
Kleiman, NS
Lincoff, AM
Flaker, GC
Pieper, KS
Wilcox, RG
Berdan, LG
Lorenz, TJ
Cokkinos, DV
Simoons, ML
Boersma, E
Topol, EJ
Califf, RM
Harrington, RA
Citation: Ns. Kleiman et al., Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes, CIRCULATION, 101(7), 2000, pp. 751-757
Authors:
Boersma, E
Pieper, KS
Steyerberg, EW
Wilcox, RG
Chang, WC
Lee, KL
Akkerhuis, KM
Harrington, RA
Deckers, JW
Armstrong, PW
Lincoff, AM
Califf, RM
Topol, EJ
Simoons, ML
Citation: E. Boersma et al., Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation results from an international trial of 9461 patients, CIRCULATION, 101(22), 2000, pp. 2557-2567
Authors:
Wong, CK
White, HD
Wilcox, RG
Criger, DA
Califf, RM
Topol, EJ
Ohman, EM
Citation: Ck. Wong et al., New atrial fibrillation after acute myocardial infarction independently predicts death: The GUSTO-III experience, AM HEART J, 140(6), 2000, pp. 878-885
Authors:
Hasdai, D
Holmes, DR
Criger, DA
Topol, EJ
Califf, RM
Wilcox, RG
Paolasso, E
Simoons, M
Deckers, J
Harrington, RA
Citation: D. Hasdai et al., Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: Effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide, AM HEART J, 139(3), 2000, pp. 454-460
Authors:
Brown, N
Melville, M
Gray, D
Young, T
Skene, AM
Wilcox, RG
Hampton, JR
Citation: N. Brown et al., Relevance of clinical trial results in myocardial infarction to medical practice: comparison of four year outcome in participants of a thrombolytic trial, patients receiving routine thrombolysis, and those deemed ineligible for thrombolysis, HEART, 81(6), 1999, pp. 598-602
Authors:
Storey, RF
May, JA
Wilcox, RG
Heptinstall, S
Citation: Rf. Storey et al., A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: Comparison with other aggregation methodologies, THROMB HAEM, 82(4), 1999, pp. 1307-1311
Authors:
Brown, N
May, JA
Wilcox, RG
Allan, LM
Wilson, AM
Kiff, PS
Heptinstall, S
Citation: N. Brown et al., Comparison of antiplatelet activity of microencapsulated aspirin 162.5 mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis, BR J CL PH, 48(1), 1999, pp. 57-62
Authors:
Ohman, EM
Armstrong, PW
White, HD
Granger, CB
Wilcox, RG
Weaver, WD
Gibler, WB
Stebbins, AL
Cianciolo, C
Califf, RM
Topol, EJ
Citation: Em. Ohman et al., Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction, AM J CARD, 84(11), 1999, pp. 1281-1286
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes
Authors:
Alexander, JH
Harrington, RA
Tuttle, RH
Berdan, LG
Lincoff, AM
Deckers, JW
Simoons, ML
Guerci, A
Hochman, JS
Wilcox, RG
Kitt, MM
Eisenberg, PR
Califf, RM
Topol, EJ
Karsh, K
Ruzyllo, W
Stepinska, J
Widimsky, P
Boland, JB
Armstrong, PW
Citation: Jh. Alexander et al., Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes, AM J CARD, 83(8), 1999, pp. 1147-1151
Authors:
Gibler, WB
Wilcox, RG
Bode, C
Castaigne, AD
Delooz, H
Elich, D
Fox, KAA
Kereiakes, DJ
Rupprecht, H
Topol, EJ
Citation: Wb. Gibler et al., Prospective use of glycoprotein IIb/IIIa receptor blockers in the emergency department setting, ANN EMERG M, 32(6), 1998, pp. 712-722
Risultati:
1-23
|